Company
Headquarters: Nedlands, WA, Australia
| Company | Market Cap (USD) |
|---|---|
| Novo Nordisk | $158.96 B |
| Vertex Pharmaceuticals Incorporated | $115.92 B |
| CSL Limited | $95.75 B |
| Regeneron Pharmaceuticals, Inc. | $82.28 B |
| Marinomed Biotech AG | $70.11 B |
| Company | Market Cap (USD) |
|---|---|
| Lilly | $968.50 B |
| Johnson & Johnson | $499.57 B |
| AbbVie | $405.28 B |
| Roche | $332.12 B |
| UnitedHealth Group | $304.72 B |
Argenica Therapeutics Limited researches and develops a neuroprotective therapeutic drug in Australia. The company's product is ARG-007, a neuroprotective peptide candidate for use in the protection of brain tissue against damage during a stroke and other acute central nervous system injuries. Argenica Therapeutics Limited was incorporated in 2019 and is based in Nedlands, Australia.
Argenica Therapeutics Ltd has the following listings and related stock indices.
Stock: ASX: AGN